基于自然杀伤细胞的癌症免疫疗法：从基础生物学到临床开发。
NK cell-based cancer immunotherapy: from basic biology to clinical development.
机构信息
Department of Urology, Feinberg School of Medicine, Northwestern University, 303 E. Superior St., Lurie Research Building 6-117, Chicago, IL, 60611, USA.
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
出版信息
J Hematol Oncol. 2021 Jan 6;14(1):7. doi: 10.1186/s13045-020-01014-w.
Abstract
Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has gained significant attention in the field of cancer immunotherapy. Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. In this review, we provide our current understandings of NK cell biology, ongoing pre-clinical and clinical development of NK cell-based therapies and discuss the progress, challenges, and future perspectives.
摘要
自然杀伤 (NK) 细胞是一种专门的免疫效应细胞类型，在针对异常细胞的免疫激活中发挥着关键作用。与 T 细胞激活所需的事件不同，NK 细胞的激活受 NK 受体与靶细胞相互作用的控制，而与抗原加工和呈递无关。由于激活的线索相对不复杂，NK 细胞在癌症免疫治疗领域引起了广泛关注。许多开发和设计基于 NK 细胞的癌症免疫疗法的努力正在涌现。在这篇综述中，我们提供了对 NK 细胞生物学的当前理解，正在进行的基于 NK 细胞的疗法的临床前和临床开发，并讨论了进展、挑战和未来展望。
相似文献
1
NK cell-based cancer immunotherapy: from basic biology to clinical development.基于自然杀伤细胞的癌症免疫疗法：从基础生物学到临床开发。
J Hematol Oncol. 2021 Jan 6;14(1):7. doi: 10.1186/s13045-020-01014-w.
2
Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.针对肿瘤微环境定制自然杀伤细胞免疫疗法。
Semin Immunol. 2017 Jun;31:30-36. doi: 10.1016/j.smim.2017.09.001. Epub 2017 Sep 19.
3
NK cell-based immunotherapy for cancer.基于自然杀伤细胞的癌症免疫疗法。
Semin Immunol. 2017 Jun;31:37-54. doi: 10.1016/j.smim.2017.07.009. Epub 2017 Aug 31.
4
Leveraging natural killer cells for cancer immunotherapy.利用自然杀伤细胞进行癌症免疫治疗。
Immunotherapy. 2017 May;9(6):487-497. doi: 10.2217/imt-2017-0013.
5
NK cell-based cancer immunotherapy: from basic biology to clinical application.基于自然杀伤细胞的癌症免疫疗法：从基础生物学到临床应用
Sci China Life Sci. 2015 Dec;58(12):1233-45. doi: 10.1007/s11427-015-4970-9. Epub 2015 Nov 20.
6
CAR-NK Cells: From Natural Basis to Design for Kill.嵌合抗原受体自然杀伤细胞：从天然基础到杀伤设计。
Front Immunol. 2021 Dec 14;12:707542. doi: 10.3389/fimmu.2021.707542. eCollection 2021.
7
NK cells to cure cancer.自然杀伤细胞治疗癌症。
Semin Immunol. 2019 Feb;41:101272. doi: 10.1016/j.smim.2019.03.004. Epub 2019 May 10.
8
[Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].[同种异体嵌合抗原受体自然杀伤细胞：自体嵌合抗原受体T细胞的一种有前景的替代方案——现状、自然杀伤细胞来源、局限性与前景]
Bull Cancer. 2021 Oct;108(10S):S81-S91. doi: 10.1016/j.bulcan.2021.06.007.
9
Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.使用克隆性自然杀伤细胞系NK-92对恶性肿瘤进行细胞免疫治疗。
J Hematother Stem Cell Res. 2001 Aug;10(4):535-44. doi: 10.1089/15258160152509145.
10
NK cells and Immunotherapy.自然杀伤细胞与免疫疗法。
Semin Immunol. 2017 Jun;31:1-2. doi: 10.1016/j.smim.2017.09.008.
引用本文的文献
1
Integration of humanized ROBO1 CAR in PD-1 locus in natural killer cells delivers synergistic tumor-killing effect against non-small cell lung cancer.将人源化ROBO1嵌合抗原受体（CAR）整合到自然杀伤细胞的PD-1基因座中，可对非小细胞肺癌产生协同抗肿瘤作用。
Cancer Gene Ther. 2025 Sep 5. doi: 10.1038/s41417-025-00957-x.
2
Recognition of molecular clusters and a novel prognostic signature based on natural killer cell-related genes in skin cutaneous melanoma.皮肤黑色素瘤中基于自然杀伤细胞相关基因的分子簇识别及一种新的预后特征
World J Surg Oncol. 2025 Sep 3;23(1):332. doi: 10.1186/s12957-025-03975-z.
3
PD-1 Bispecific Killer Engager (PD-1 BiKE) effectively depletes effector T lymphocytes in experimental autoimmune encephalomyelitis.程序性死亡蛋白1双特异性杀伤衔接分子（PD-1双特异性衔接分子，PD-1 BiKE）可有效耗竭实验性自身免疫性脑脊髓炎中的效应性T淋巴细胞。
Front Immunol. 2025 Aug 13;16:1644903. doi: 10.3389/fimmu.2025.1644903. eCollection 2025.
4
Donor Variability and Seeding Density Shape NK-Cell Proliferation and Surface Receptor Expression: Insights from an Integrated Phenotypic and Genetic Analysis.供体变异性和接种密度塑造自然杀伤细胞增殖及表面受体表达：来自综合表型与基因分析的见解
Cells. 2025 Aug 14;14(16):1252. doi: 10.3390/cells14161252.
5
Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.释放自然杀伤细胞用于肺癌的癌症免疫治疗：生物学挑战与临床进展
J Exp Clin Cancer Res. 2025 Aug 23;44(1):251. doi: 10.1186/s13046-025-03503-7.
6
Isoliensinine inhibits mitophagy and sensitizes T cell malignancies for STING-mediated NK clearance.异莲心碱抑制线粒体自噬并使T细胞恶性肿瘤对STING介导的自然杀伤细胞清除作用敏感。
Acta Pharmacol Sin. 2025 Aug 21. doi: 10.1038/s41401-025-01636-1.
7
Adoptive cell therapy for cancer: combination strategies and biomarkers.癌症的过继性细胞疗法：联合策略与生物标志物
Front Immunol. 2025 Aug 1;16:1603792. doi: 10.3389/fimmu.2025.1603792. eCollection 2025.
8
NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.自然杀伤细胞衍生的细胞外囊泡增强非小细胞肺癌中的细胞毒性和免疫细胞募集。
Front Immunol. 2025 Jul 24;16:1633010. doi: 10.3389/fimmu.2025.1633010. eCollection 2025.
9
Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study.补中益气汤对接受免疫检查点抑制剂治疗的非小细胞肺癌患者免疫反应和临床结局的影响：一项随机试验研究
BMC Cancer. 2025 Jul 29;25(1):1229. doi: 10.1186/s12885-025-14629-4.
10
Role of the TLR signaling pathway in the pathogenesis of glioblastoma multiforme with an emphasis on immunotherapy.Toll样受体（TLR）信号通路在多形性胶质母细胞瘤发病机制中的作用，重点在于免疫治疗。
Biochem Biophys Rep. 2025 Jul 18;43:102149. doi: 10.1016/j.bbrep.2025.102149. eCollection 2025 Sep.
本文引用的文献
1
Exploring the NK cell platform for cancer immunotherapy.探索自然杀伤细胞平台在癌症免疫疗法中的应用。
Nat Rev Clin Oncol. 2021 Feb;18(2):85-100. doi: 10.1038/s41571-020-0426-7. Epub 2020 Sep 15.
2
Tissue-Resident NK Cells: Development, Maturation, and Clinical Relevance.组织驻留自然杀伤细胞：发育、成熟及临床意义
Cancers (Basel). 2020 Jun 12;12(6):1553. doi: 10.3390/cancers12061553.
3
DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.DNAM1和2B4共刺激结构域增强抗GPC3嵌合抗原受体修饰的自然杀伤细胞对肝癌细胞的体外细胞毒性。
Cancer Manag Res. 2020 May 8;12:3247-3255. doi: 10.2147/CMAR.S253565. eCollection 2020.
4
A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis.一种新型嵌合型PD1-NKG2D-41BB受体通过触发细胞焦亡增强NK92细胞对人肺癌H1299细胞的抗肿瘤活性。
Mol Immunol. 2020 May 6;122:200-206. doi: 10.1016/j.molimm.2020.04.016.
5
Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development.在哺乳动物发育过程中，具有强大细胞毒性的自然杀伤细胞最初从红细胞-髓样祖细胞中出现。
Dev Cell. 2020 Apr 20;53(2):229-239.e7. doi: 10.1016/j.devcel.2020.02.016. Epub 2020 Mar 19.
6
Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.诱导多能干细胞衍生的抗 GPC3 嵌合抗原受体表达的自然杀伤/固有淋巴细胞的非临床疗效、安全性和稳定的临床细胞处理。
Cancer Sci. 2020 May;111(5):1478-1490. doi: 10.1111/cas.14374. Epub 2020 Mar 31.
7
High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.慢病毒和阿尔法逆转录病毒工程化 CD19 特异性嵌合抗原受体自然杀伤细胞对急性淋巴细胞白血病的高效细胞毒性。
Front Immunol. 2020 Jan 24;10:3123. doi: 10.3389/fimmu.2019.03123. eCollection 2019.
8
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.组织因子作为三阴性乳腺癌 CAR-NK 细胞免疫治疗的新靶点。
Sci Rep. 2020 Feb 18;10(1):2815. doi: 10.1038/s41598-020-59736-3.
9
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
10
Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).基于纳米抗体的嵌合抗原受体（Nb-CARs）体外靶向表达 CD38 的多发性骨髓瘤和伯基特淋巴瘤细胞。
Cells. 2020 Jan 29;9(2):321. doi: 10.3390/cells9020321.
Zotero 插件